Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 238-877-9 | CAS number: 14807-96-6
Specific investigations: other studies
Administrative data
Link to relevant study record(s)
Description of key information
-In the study of Yasuhiro Toba et al 2000, the results indicate that magnesium supplementation reduces apparent calcium absorption, but promotes bone formation and prevents bone resorption in OVX rats. Moreover, our results indicate magnesium supplementation increases the dynamic strength of bone.
-In the study of Clark I, 1968, the rats supplemented with magnesium developed loose stools and diarrhoea for the first few days.
Additional information
- In the study of Yasuhiro Toba et al 2000, the autors evaluated the effect of magnesium supplementation on apparent calcium absorption, bone metabolism and dynamic bone strength in ovariectomized (OVX) rats as a model of postmenopausal women. Two groups of OVX rats were fed a 0.05% Mg diet or a 0.15% Mg diet, and one group of sham-operated rats was fed the 0.05% Mg diet for 42 d. We collected feces and urine of all rats for 3-d periods starting from d 3, 10, 17, 24, 31 and 38 of the feeding experiment for calcium and magnesium balance studies. Urine was collected for 24 h from d 41 of the feeding experiment for measuring deoxypyridinoline. After the 42 d, the rats were killed, serum prepared and femora excised. The apparent calcium absorption in the OVX rats fed 0.15% Mg was significantly lower than both other groups. Additionally, the urinary excretion of deoxypyridinoline (a bone resorption marker) and the serum parathyroid hormone level of the OVX rats fed the 0.15% Mg diet were significantly lower than in the OVX rats fed 0.05% Mg. Serum osteocalcin (a bone formation marker) in the OVX rats fed the 0.15% Mg diet was significantly higher than in the OVX rats fed 0.05% Mg. The breaking force and breaking energy of the femur in the OVX rats fed the 0.15% Mg diet were significantly higher than in the OVX rats fed the 0.05% Mg diet.
These results indicate that magnesium supplementation reduces apparent calcium absorption, but promotes bone formation and prevents bone resorption in OVX rats. Moreover, our results indicate magnesium supplementation increases the dynamic strength of bone.
- In the study ofClark I, 1968, the rats supplemented with magnesium developed loose stools and diarrhoea for the first few days.
If the diets contained adequate amounts of calcium, supplemental magnesium decreased faecal calcium (increased absorption) and increased urinary calcium irrespective of the dietary level of calcium. The net effect of supplemental magnesium was to increase calcium balance. The mechanism for the increased absorption of calcium from the intestinal tract or the hypercalciuria is not known. Supplemental magnesium had no effect on phosphorous absorption when dietary phosphorous was suboptimal; it increased it when the dietary calcium to phosphorous ratio was low. The effects of magnesium on phosphate absorption appear to be the result of a magnesium-calcium interaction. Urinary phosphorous decreased with increasing magnesium intake. In general, magnesium increased phosphorous balance primarily as a result of renal conservation of phosphorous.
There are significant interrelations between dietary phosphorous and magnesium as well as between calcium and magnesium in the absorption and homeostatic control of these substances.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
